IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals.

Due to the growing interest of International Atomic Energy Agency (IAEA) Member States in implementing targeted radionuclide therapy (TRT) in general, the demand for alpha-emitting radionuclides and radiopharmaceuticals is enormous. As an international platform for peaceful applications of radionuclides, the IAEA has been implementing several activities focusing on the production and quality control of alpha emitters and radiopharmaceuticals as well as capacity building in the field, through Technical Meetings, Workshops, Publications and Conference Supports, IAEA-Coordinated Research Projects (CRP) and Technical Cooperation Program (TC). This review article summarises the IAEA activities on the production and quality control of alpha emitter radiopharmaceuticals for targeted alpha therapy (TAT) and a roadmap to future steps including but not limited to the ongoing CRP on Ac-radiopharmaceuticals.

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Background: Cancer immunotherapy is a relatively new approach to cancer treatment. Peptides that target specific pathways and cells involved in immunomodulation can potentially improve the efficacy of cancer therapy. Recently, we reported iPD-L1 as a novel inhibitor peptide that specifically targets the cancer cell ligand PD-L1 (programmed death ligand 1).

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Prostate cancer (PC) represents the second most diagnosed form of cancer in men on a global scale. Despite the theranostic efficacy of prostate-specific membrane antigen (PSMA) radioligands, there is a spectrum of PC disease in which PSMA expression is low or absent. The gastrin-releasing peptide receptor (GRPR), also known as the bombesin type 2 receptor, has been identified as a target in both the early and advanced stages of PC.

An Overview of Film-Forming Emulsions for Dermal and Transdermal Drug Delivery.

Drug delivery through the skin is a widely used therapeutic method for the treatment of local dermatologic conditions. Dermal and transdermal methods of drug delivery offer numerous advantages, but some of the most important aspects of drug absorption through the skin need to be considered. Film-forming systems (FFS) represent a new mode of sustained drug delivery that can be used to replace traditional topical formulations such as creams, ointments, pastes, or patches.

Enhancing photodynamic and radionuclide therapy by small interfering RNA (siRNA)-RAD51 transfection via self-emulsifying delivery systems (SNEDDS).

Background Aims: Gene-silencing by small interfering RNA (siRNA) is an attractive therapy to regulate cancer death, tumor recurrence or metastasis. Because siRNAs are easily degraded, it is necessary to develop transport and delivery systems to achieve efficient tumor targeting. Self-nanoemulsifying systems (SNEDDS) have been successfully used for pDNA transport and delivery, so they may be useful for siRNA.